Healthcare
LENSAR, Inc.(LNSR)
Live Price
Offline$5.82
+0.00% today
1Y Change
-51.52%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $70.00M
- Revenue Growth
- +9.2%
- EPS Growth
- -5.1%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
LENSAR, Inc. (LNSR) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $5.82 and down 51.5% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +9.2%, EPS growth of -5.1%, a dividend yield of 0.0%. What stands out right now is revenue +9.2%, EPS -5.1%, free cash flow -513.5% with operating margin -42.1% and ROIC -77.8%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines LNSR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+9.2% vs +7.6% peer median
Operating Margin
Below sector median
-42.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +9.2% and EPS is at -5.1%, with operating margin around -42.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 7, 2026 | โ | +7.8% | +11.5% | +7.1% |
2026 Mar 31, 2026 | -80.7% | +0.2% | -7.2% | -9.6% |
2025 Nov 6, 2025 | -210.0% | -7.3% | -10.4% | -2.1% |
Benchmark Edge
LNSR vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LNSR
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LNSR Max Drawdown
-61.79%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LNSR and SPY.
Company Overview
LENSAR, Inc.
NASDAQ Capital Market
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
- Leadership
- Nicholas T. Curtis
- IPO Date
- Oct 2, 2020
- Employees
- 140
- Street Address
- 2800 Discovery Drive
- Mailing
- Orlando, FL, 32826
- Region
- Orlando, FL, US
- Reporting Currency
- USD
- Investor Line
- 888 536 7271
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.2
- Price/Book
- โ
Growth
- Revenue
- +9.2%
- EPS
- -5.1%
- Free Cash Flow
- -513.5%
Profitability
- Gross Margin
- 46.0%
- Operating Margin
- -42.1%
- Net Margin
- -58.7%
- ROE
- 197.2%
- ROIC
- -77.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 1.15
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.